https://doi.org/10.55788/65341f6e
Prof. Ulrich Specks (Mayo Clinic, MN, USA) presented the respiratory and ENT outcomes of the phase 3 ADVOCATE trial (NCT02994927) [1]. ADVOCATE was a phase 3, randomised, double-blind, double-dummy, controlled clinical study comparing the selective neutrophil C5aR inhibitor avacopan (plus prednisone-matching placebo) with prednisone (plus avacopan-matching placebo) in addition to either cyclophosphamide (followed by azathioprine) or rituximab. The previously published primary results demonstrated the efficacy of avacopan in helping patients with ANCA-associated vasculitis achieve disease remission at 6 months and sustained remission at 12 months [2].
When the 330 patients included in the current subgroup analysis were stratified by the phenotype of their disease, pulmonary involvement was more common in patients with granulomatosis with polyangiitis (54%; 98/181) than with microscopic polyangiitis (30%; 45/149). The primary endpoint was the percentage of participants achieving disease remission at week 26 and sustained remission at week 52. Disease remission was defined as a Birmingham Vasculitis Activity Score (BVAS) of 0 and no glucocorticoids within 4 weeks prior to week 26. Sustained remission was remission at week 26 and week 52 and no glucocorticoid use at 4 weeks prior to week 52. Lung and ENT involvement was defined as BVAS-detected active vasculitis in the upper and lower respiratory tract.
The results indicated an overall glucocorticoid use reduction by a median of 86% in the avacopan group, with data pointing to a 26-week non-inferiority significance, improving to a 52-week superiority significant remission compared with the prednisone group. Although rates of both lung and ENT involvement were numerically lower in the avacopan group than in the prednisone group, the differences were not statistically significant. At baseline, 43% of patients (143/330) had evident lung involvement. At weeks 26 and 52, lung involvement was present in 0.6% (1/166) and 0% (0/166) of participants in the avacopan group, respectively. In comparison, at weeks 26 and 52, 2.4% (4/164) and 1.8 % (3/164) of participants in the prednisone group, respectively, had lung involvement. Similarly, ENT involvement at baseline was present in 44% of participants (144/330). In the avacopan group, ENT involvement was present in 1.2% (2/166) of participants at both weeks 26 and 52. In the prednisone group, ENT involvement was present in 3.7% (6/164) and 3.0% (5/164) of participants, at weeks 26 and 52, respectively.
āThe overall results of the ADVOCATE trial are very exciting as they indicate that patients with ANCA-associated vasculitis receiving avacopan can achieve sustained remission with minimal glucocorticoid exposure,ā Prof. Specks said. āWhile the results presented here for the subset of patients with lung and ENT involvement are most promising, the specific effect of avacopan on individual disease manifestations requires further study.ā
- Specks U, et al. Insights from the ADVOCATE study: Respiratory tract involvement in patients with ANCA-associated vasculitis in a randomised, double-blind, placebo-controlled phase 3 trial of avacopan. Session C93, ATS International Conference 2022, San Francisco, CA, USA, 13ā18 May.
- Jayne DRW, et al. N Engl J Med 2021;384(7):599ā609.
Copyright Ā©2022 Medicom Medical Publishers
Posted on
Previous Article
« PAGANINI phase 2b data promising for eliapixant Next Article
Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis »
« PAGANINI phase 2b data promising for eliapixant Next Article
Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis »
Table of Contents: ATS 2022
Featured articles
Letter from the Editor
COVID-19
Nebulised aviptadil āfutileā in I-SPY COVID-19 trial
Lung transplantation after COVID-19-associated ARDS
Mesenchymal stem cells offer no benefit in COVID-19
Alpha-1 antitrypsin for ARDS secondary to severe COVID-19
Frailty prevalent 5 months following hospitalisation for COVID-19
Paediatric long COVID lacks definitions
Asthma Clinical Trial Updates
MANDALA and DENALI pattern success for albuterol-budesonide in asthma
ACOUSTICS data sounds good for adolescent asthma exacerbations
Type 2 asthma in children managed by dupilumab, despite atopic comorbidities
NAVIGATOR steers asthma patients to tezepelumab
High-intensity interval training slashes daily corticosteroids in asthma
Chronic Obstructive Pulmonary Disease
Threeās a crowd for triple therapy in COPD
Higher 1-year COPD mortality after hospitalisation for White patients
Reducing dyspnoea in chronic lung disease through weight loss
CT-evident mucus plugs in COPD associated with death
Home-based rehabilitation improves COPD: a randomised study
Highlighted Advances
Novel P2X3 antagonist can SOOTHE chronic cough
Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis
Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?
PAGANINI phase 2b data promising for eliapixant
POISE-3: Tranexamic acid for non-cardiac surgery
Obstructive sleep apnoea in most children with pulmonary hypertension
No screening evidence for COPD
Novel PDE4B inhibitor offers breakthrough for IPF
Hydrocortisone does not help preterm infants
CPAP temporarily supports pulmonary oxygenation in morbidly obese patients
ISAACC trial: CPAP controls blood pressure in ACS patients with severe OSA
Related Articles
October 30, 2022
Impact of CPAP on cardiac endpoints in OSA
October 30, 2022
Sustained hypoxaemia predicts unprovoked VTE in OSA
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com